Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca Plc’s chief executive officer broke ranks with his pharmaceutical industry peers Tuesday, saying he was open to ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

The White House cited data showing brand-name drugs in the United States are up to three times more expensive than identical drugs in other developed nations.